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Abstract
Background: Matriptase is a type II transmembrane serine protease that is found on the surfaces of epithelial cells
and certain cancer cells. Matriptase has been implicated in the degradation of certain extracellular matrix
components as well as the activation of various cellular proteins and proteases, including hepatocyte growth factor
and urokinase. Sunflower trypsin inhibitor-1 (SFTI-1), a cyclic peptide inhibitor originally isolated from sunflower
seeds, exhibits potent inhibitory activity toward matriptase.
Results: We have engineered and produced recombinant proteins of the matriptase protease domain, and have
determined the crystal structures of the protease:SFTI-1 complex at 2.0 Å as well as the protease:benzamidine
complex at 1.2 Å. These structures elaborate the structural basis of substrate selectivity of matriptase, and show
that the matriptase S1 substrate specificity pocket is larger enough to allow movement of benzamidine inside the
S1 pocket. Our study also reveals that SFTI-1 binds to matriptase in a way similar to its binding to trypsin despite
the significantly different isoelectric points of the two proteins (5.6 vs. 8.2).
Conclusions: This work helps to define the structural basis of substrate specificity of matriptase and the
interactions between the inhibitor and protease. The complex structure also provides a structural template for
designing new SFTI-1 derivatives with better potency and selectivity against matriptase and other proteases.
Background
Matriptase is a type II transmembrane serine protease of
the S1 trypsin-like family. Matriptase activity is down-
regulated by its physiological inhibitor, hepatocyte
growth factor activator inhibitor-1 (HAI-1) [1-3].
Matriptase is expressed in most epithelial cells and plays
essential roles in the establishment and maintenance of
epithelial integrity. New evidence suggests that matrip-
tase is also expressed on mast cells, peripheral blood
monocytes and B cells, implicating matriptase in the
physiological and pathologic functions of these cells
[4-6]. Knock down studies in mice have shown that the
protease is important in postnatal survival, epidermal
barrier formation, hair follicle growth and thymicho-
meostasis [7]. At the same time, genetic studies using
zebra fish and mice have indicated that the activity of
matriptase is critical for tissue-integrity and function,
and must be strictly controlled by HAI-1 [8-11].
The catalytic domain of matriptase is tethered to the
cell surface via its N-terminal signal anchor, linked by a
sea urchin sperm protein/enterokinase/agrin (SEA)
domain, two tandem complement/urchin embryonic
growth factor/bone morphogenetic protein (CUB)
domains, and four tandem low-density lipoprotein
receptor class A (LDLRA) domains. Interestingly,
matriptase activation does not depend on other active
proteases. Instead, several lines of evidence have indi-
cated that matriptase undergoes autoactivation through
a mechanism relying on its own catalytic triad and
requires its non-catalytic domains as well as the pre-
s e n c eo fi t sc o g n a t ei n h i b i t o rH A I - 1[ 1 2 , 1 3 ] .A l t h o u g h
the autoactivation mechanism is not fully understood,
one study has showed that matriptase could be activated
by acidification, and suggested that matriptase might act
as an early response to cellular acidosis [14]. Once acti-
vated, matriptase has only short time to cleave and acti-
vate its substrates since the protease will be quickly
inhibited by HAI-1.
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G-protein-coupled protease-activated receptor 2, uroki-
nase plasminogen activator and pro-hepatocyte growth
factor [15,16]. Recently, it has been demonstrated that
matriptase could also activate prekallikren either in vitro
or in vivo [17]. Matriptase is recognized as a cancer-asso-
ciated protease since the activation of urokinase plasmino-
gen activator and/or pro-hepatocyte growth factor has
been implicated in cancer invasion and metastasis
(reviewed in [18]). In addition, matriptase has been found
to be upregulated in various forms of cancers including
breast, cervical, ovarian, liver, and prostate cancers. It has
been demonstrated that the level of expression of matrip-
tase correlates with the tumor stage and malignancy of
breast, cervical, ovarian and prostate cancers [19-21]. In
some of these cancers, the ratios of the protease relative to
its inhibitor HAI-1 are unbalanced; suggesting that strict
regulation of matriptase by HAI-1 is required to prevent
carcinogenesis. A recent study showed that matriptase
orthotopically overexpressed at modest levels in the skin
of transgenic mice caused spontaneous squamous cell
carcinoma, potentiated chemical carcinogenesis, and sup-
ported both ras-dependent and -independent carcinogen-
esis, whereas the overexpression of HAI-1 could nullify
these oncogenic effects [22]. In addition to its role in can-
cers, recent studies have suggested that matriptase also
has potential implications in a variety of diseases including
osteroarthritis, atherosclerosis, and skin disorders like
autosomal recessive ichthyosis and hypotrichosis (ARIH)
[4,23-26]. Taken together, matriptase has emerged as an
attractive target for the development of anti-metastasis
therapy as well as treatment for many other diseases.
Sunflower trypsin inhibitor-1 (SFTI-1), a 14-amino
acid cyclic peptide, is originally isolated from sunflower
seeds and characterized as the most potent peptidic
inhibitor of trypsin (Ki = 0.1 nM and 1 nM from two
independent studies) [27,28]. A later study finds that
synthetic SFTI-1 also exhibits very potent matriptase
inhibitory activity (Ki = 0.92 nM) [27]. To evaluate the
structural basis of the high inhibitory effect of SFTI-1 to
matriptase, we have determined the X-ray structure of
matriptase in complex with SFTI-1. We have also deter-
mined the high-resolution structure of matriptase:benza-
midine complex for structural comparison. The crystal
structures provide new insights into the molecular basis
of matriptase inhibition and this information might
facilitate future design of more potent and selective pep-
tide inhibitors using SFTI-1 as template.
Results and Discussion
Engineering of recombinant matriptase catalytic domain
in P. pastoris for structural study
For our structural studies, we constructed a recombi-
nant protease domain of matriptase (residue 615 to 854
of the EXPASY entry Q9Y5Y6) with a point mutation
N164Q (chymotrypsin numbering will be used through-
out the paper starting from here), which is referred as
b-matriptase-N164Q. The point mutation removes a
glycosylation site (N164) and allows the protein to be
purified to homogeneity. Another unique feature of the
current design of the expression scheme is that the
secreted recombinant matriptase protease domain is an
active serine protease without the need of being acti-
vated. This is due to the processing of the secreted pro-
tein by an endogenous kex2 enzyme of P. pastoris that
generates the genuine N-terminus of matriptase protease
domain and allows the correct folding of the protease
into its active form. We have used such approach to
generate a number of active proteases including uroki-
nase-type plasminogen activator [29], tissue-type plasmi-
nogen activator and coagulation factor XIa (to be
published), suggesting that our method can be widely
adapted for the expression of different active proteases.
Structure of b-matriptase-N164Q:benzamidine shows
benzamidine mobility
In the structure of b-matriptase-N164Q complexed with
benzamidine, the benzamidine binds to the specificity
pocket S1 right next to the active site and is sandwiched
by the segments of Ser190-Gln192 and Trp215-Gly216 as
expected. This structure is similar to the previously
reported structure of the matriptase protease domain in
complex with benzamidine (PDB ID = 1EAX, RMSD =
0.1 Å for the Ca atoms of 227 residues) [30]. However,
there are interesting differences between these two struc-
tures. The phenyl group of the benzamidine in our struc-
ture shows a 35° rotation when compared to the 1EAX
structure. While the amidino group of the inhibitor jux-
taposes the side chain of Asp189 and forms favorable
ionic interaction with its carboxylate group as in the
1EAX structure, the bis-amine in our structure is rotated
for ~20° and makes an extra hydrogen bond with the
backbone carbonyl of Ser190, in addition to those formed
with the Gly219 carboxylate and a conserved solvent
molecule in 1EAX (Figure 1). Considering the high reso-
lutions of both matriptase-benzamidine structures (1.2 Å
in our structure) and the relatively small errors of struc-
tures (0.4 Å in our structure), such differences in benza-
midines are significant, and indicates that S1 pocket is
larger than the molecular size of benzamidine and allows
movement of benzamidine inside the S1 specificity
pocket. This is consistent with the observed higher tem-
perature factor of benzamidine (40 Å
2) comparing to the
average temperature factor of protein (15 Å
2).
Interactions between matriptase and SFTI-1 at the active site
Since SFTI-1 is a highly potent inhibitor to either
matriptase or trypsin with comparable potencies, we
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same for the two proteases. The crystal structure of b-
matriptase-N164Q in complex with SFTI-1 was solved
at 2.0 Å (Figure 2A). In this structure, SFTI-1 forms a
bicyclic structure where two antiparallel b-strands are
constrained by a disulfide bond between Cys3 and
Cys11 (Figure 2B). The cyclic peptidic inhibitor docks
onto matriptase’sP 4 - P 2 ’ specificity sites with good
shape and charge complementarity. This resembles the
SFTI-1 binding to trypsin and other BBI to serine pro-
teases, as well as the reactive site loop of the bovine
pancreatic trypsin inhibitor (BPTI) to matriptase
[28,30-33]. Like the equivalent side chains in the other
complexes, Lys5 from the “reactive loop” of SFTI-1
extends into the S1 pocket of matriptase to form a
hydrogen bond directly with Ser190 and may also inter-
act with Asp189 at the bottom of the pocket (Figure 2C
and Table 1; Table 1 summarizes hydrogen bonds
formed between matriptase and SFTI-1). The SFTI-1
scissile bond (Lys5-Ser6) is in close proximity to the cat-
alytic residue Ser195 where the Ser195 hydroxyl group
hydrogen bonds with the main-chain amide of Ser6 and
makes close contacts with the backbone carbonyl and
amide of Lys5 (2.9Å and 3.0 Å respectively). The side
chain oxygen atom of Ser195 is also in close contact
with the carbonyl carbon of P1 residue (Lys5) (2.6 Å) at
an angle of 88.6° (Lys5O-C-Ser195OG), suggesting the
protease is in an active conformation capable of
initiating bond scission. Furthermore, His57 is suitably
oriented to interact with Ser195 to support catalysis (at
2.6 Å and with Ser195CB-OG-His57NE2 angle of
101.4°). These observations support that SFTI-1 func-
tions as a substrate variant of matriptase in a similar
manner to other BBIs. Thus, the cyclic peptidic inhibitor
is likely to inhibit the enzyme through high affinity
binding to the active site and through excluding water
molecules from the active site to destabilize the reac-
tion-path transition state.
Comparison of the conformations of matriptase in the
benzamidine- and SFTI-1-bound forms reveals that they
are nearly identical except the side chain of Phe99 at
the S2 subsite, which will be discussed later, and Gln192
at the S3 subsite. Gln192 side chain is solvent-exposed
in the benzamidine-bound structure and forms the lin-
ing of the extended active site groove. However, it
undergoes a major conformational change to “bend
inward” to accommodate SFTI-1 and hydrogen bonds
with the backbone carbonyl of Thr4 of the cyclic inhibi-
tor in a manner similar to that in the BPTI-bound
matriptase structure.
Substrate selectivity of matriptase
Previous studies using positional scanning-synthetic
combinatorial library and substrate phage display have
revealed that matriptase also strongly prefers substrates
with small residues including glycine and serine, or
Figure 1 Comparison of benzamidine orientations in two matriptase:benzamidine complexes. Benzamidine mediates extra hydrogen
bonding and van der Waals interactions to the peptide segment of Ser190-Gln192 in our structure (blue) when compared to 1EAX (yellow).
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tease specificity for basic residue at the P1 pocket [16].
Moreover, the most effective substrate has been found
to contain basic residues at the P3 or P4 sites, but not
both simultaneously [16]. Indeed, the sequence of
SFTI-1 matches these findings except the presence of a
threonine at the P2 position. Our structure explains
how SFTI-1 achieves such substrate selectivity. In the
structure, the S2 subsite of matriptase is occupied by
SFTI-1 Thr4 with Thr4 side chain flanked by His57
and Phe99. The methyl group of Thr4 makes CH-π
interaction with both flanking side chains and docks
snugly in the pocket. Comparing to the benzamidine-
bound structure, we observed that the benzyl ring of
Phe99 undergoes a rotation to widen the pocket to
better accommodate the P2 residue (Figure 3A). Simi-
lar observation has also been made in the BPTI:matrip-
tase complex [30]. This structural explanation for the
suitability of threonine at P2 position suggests that the
S2 pocket is not rigid and its size is controlled by the
conformation of Phe99. A large residue at substrate P2
position will inevitably cause steric hindrance with
His57 and alter its position, and will disrupt the hydro-
gen bond between Asp102 and His57 and hinder cata-
lysis. Yet, despite its large size, a phenylalanine at P2
would make favorable π-π interactions with Phe99 and
His57, and/or cation-π interaction when the histidine
is protonated during catalysis, explaining why phenyla-
lanine is also preferred in addition to small residues at
this site [16].
Figure 2 Crystal structure of matriptase:SFTI-1 complex. A) Overall structure of SFTI-1-bound matriptase in surface rendition (grey) with SFTI-
1 in cyan. B) SFTI forms a bicyclic structure. 2Fo-Fc electron density map of the peptide inhibitor contoured at 1s is shown. C) Interactions of
matriptase (grey) and SFTI-1 in stereo view. Intermolecular hydrogen bonds formed between the protease and inhibitor are denoted by dashed
lines.
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=1 S F I )r e v e a l st h a tt h eb-turn consisted of Phe12,
Pro13, Asp14 and Gly1 of SFTI-1 adopts a slightly dif-
ferent conformation upon binding to matriptase [27,28].
This is to avoid steric hindrance with the matriptase 99
loop. Particularly, both side chains of SFTI-1 Phe12 and
matriptase Phe99 (Leu99 in trypsin) undergo large rota-
tional changes to avoid clashing with each other (Figure
3A). In its new conformation, Phe12 is now stabilized
by van der Waals interaction with the benzyl rings of
Phe97 and Phe99. Gly1 consequently shifts slightly clo-
ser to the active site groove by ~0.6 Å, allowing its
main-chain carbonyl to make an extra contact with the
amide of Gly219. Interaction between Asp14 and
Gln175 of trypsin is replaced with intramolecular inter-
action between Asp14 and Arg2 of SFTI-1, which stabi-
lizes the conformation of Arg2 side chain to interact
with the S4 subsite (Figure 3B). The backbone carbonyls
of Asp95, Phe97 and Thr98 form the S4 subsite, which
is confined and protected from the solvent by the side
chains of Phe97 and Phe99 [30]. Previous positional
scanning and substrate phage display studies performed
by Takeuchi et al [16] had revealed that the S4 subsite
of matriptase strongly prefers basic residues. Our struc-
ture provides a clear explanation on this selectivity.
Firstly, unlike in the trypsin-SFTI-1 complex, the guani-
d i n i u mg r o u po fA r g 2i sa n c h o r e db yA s p 1 4t of o r m
two hydrogen bonds with the carbonyl of Phe97. Sec-
ondly, the rearrangement of the benzyl groups of Phe97
and Phe99 results in a solvent-shielding environment
that lowers the dielectric constant and thus stabilizes
the hydrogen bonding interactions mediated by Arg2
(Figure 3B). More importantly, the guanidinium group
of Arg2 forms cation-π interactions with both phenyla-
lanines as well as Trp215 in T-shaped geometries and
provides further stabilization [34,35]. To confirm these
interactions, we used the program CaPTURE to estimate
the stabilizing energies from the cation-π interactions
(Table 2) [34]. The interaction between Arg2 and the S4
subsite alone is estimated to contribute ~12 kcal/mol,
s u g g e s t i n gt h a tt h eS 4s u b s i t em a yp l a yak e yr o l ei n
matriptase specificity. Indeed, inhibitory assays with dif-
ferent SFTI-1 derivatives have shown that the S4 subsite
strongly prefers arginine [36]. Minor modifications of
the Arg2 guanidinium in SFTI-1 result in significant
loss of matriptase inhibition, and replacement of Arg2
with a Phe(Glu) decreases the inhibitory activity by 900-
fold [36].
Comparison of SFTI-1 binding to matriptase and trypsin
Matriptase protease domain contains many acidic resi-
dues, leading to a lower theoretical pI in comparison
with bovine trypsin (5.6 vs. 8.2). In addition, the electro-
static surface potential of t h ea c t i v es i t eg r o o v eo ft h e
matriptase protease domain is much more negatively
charged than that of trypsin (Figure 4A and 4B). Thus,
the basic SFTI-1 (pI = 8.1) would presumably favor
matriptase binding than trypsin binding. However,
SFTI-1 has been shown to inhibit trypsin and matriptase
with comparable affinities [27], and we observed here
that the binding interface of SFTI-1 to matriptase is
structurally very similar to trypsin. Such apparent dis-
crepancy may be due to the lower mobility of SFTI-1,
and thus stronger binding, in the current matriptase:
SFTI-1 crystal structure when compared to the trypsin:
SFTI-1 structure (relative mobility of 0.7 vs. 1.5). Here
the relative mobility is defined by the average tempera-
ture factor of SFTI-1 in the structure of the complexes
divided, by the average temperature factor of the rest of
protein in order to cancel out the effect of resolution on
the temperature factor. Another possible explanation is
to take into account the penalty of the loss of configura-
tional entropy of both protein and ligand upon SFTI-1
binding [37]. For instance, Phe12 of SFTI-1 is more con-
strained in the matriptase complex than in the trypsin
complex due to the presence of Phe97 and Phe99 that
surround it, which might result in a lower torsional
degree of freedom and yield an entropy penalty, com-
pensating the gain of enthalpy from the charge
complementarity.
Implication for future inhibitor design
The current structure provides a template for further
improvement of SFTI-1. For instance, non-polar resi-
dues like Ile7 and Ile10 are good candidates for modifi-
cations of this bicyclic peptide to improve its binding
enthalpy. Ile10 is located in a cavity formed by the sur-
face exposed insertion loops (loops 66 and 99) of
matriptase and is proximal to the active site. However,
it does not make any direct contacts with residues from
the protease. Previous work by Li et al. shows that Ile10
plays an important role in the selectivity of the inhibitor
Table 1 Hydrogen bonds between matriptase
(chymotrypsin numbering) and SFTI-1
SFTI-1 residue/atoms Matriptase residue/atoms Distance (Å)
Arg2 NH1 Phe97 O 2.8
Arg2 NH2 Phe97 O 2.9
Cys3 N Gly216 O 3.0
Cys3 O Gly216 N 3.0
Thr4 O Gln192 NE2 3.0
Lys5 N Ser214 O 3.2
Lys5 NZ Ser190 OG 2.9
Lys5 O Ser195 N 2.9
Lys5 O Gly193 N 2.8
Ser6 N Ser195 OG 3.0
Ile7 N Ile41 O 3.3
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improves the compound selectivity for matriptase versus
thrombin by >1073 fold [36]. Based on the electrostatic
surface potential of matriptase calculated from our
structure, the modification of SFTI-1 Ile10 to a posi-
tively charged amino acid might fit the cavity more
tightly and provide a favorable enthalpy. However,
increasing flexibility of the inhibitor might result in loss
of configurational entropy upon binding, as illustrated
by the higher Ki of the Gln10 derivative of SFTI-1 [36].
Therefore, flexible amino acids like lysine and arginine
should be avoided for the substitution and small posi-
tively charged unnatural amino acids such as diamino-
propionic acid or diaminobutyric acid may be used
Figure 3 Comparison of matriptase:SFTI-1 and trypisn:SFTI-1 complexes.A )T h em a t r i p t a s eP h e 9 9s i d ec h a i n s( g r e y )a n dS F T IP h e 1 2- 1
(cyan) undergo large rotation to widen the S2 subsite when compared to the structures of matriptase in benzamidine-bound form (light blue)
and trypsin: SFTI-1 complex (deep blue). B) SFTI-1 Arg2 is accommodated at the S4 subsite (in surface representation and colored by electrostatic
potential, ±7 kT/e).
Yuan et al. BMC Structural Biology 2011, 11:30
http://www.biomedcentral.com/1472-6807/11/30
Page 6 of 10instead. These small side chains will likely favor the
interaction with Asp96 without disrupting the confor-
mation of the catalytic triad and improves the enthalpy
of binding while minimizing the entropy penalty [38].
Similarly, Ile7 lies on top of a groove adjacent to the
catalytic cleft of matriptase and its sole direct interac-
tion with matriptase is through weak van der Waals
interaction with Ile41. We believe our suggested strategy
for the modification of Ile10 can also be applied to Ile7.
Together, the combination of modifications at Ile7 and
Ile10 should improve the inhibitory activity of SFTI-1
towards matriptase.
Conclusions
SFTI-1 is originally isolated and characterized as a
potent trypsin inhibitor. It has also been synthesized by
Roller’s group and shown to exhibit potent inhibitory
effect against matriptase. The same group also investi-
gated the structural basis of the high inhibitory activity
of SFTI-1 using molecular modeling study and obtained
information that aids the design and synthesis of new
SFTI-1 analogs. While modification to stabilize the dis-
ulfide bond within the cyclic peptide maintains the com-
pound’s inhibitory potency and selectivity of matriptase
versus thrombin, replacement of Ile10 with the more
polar glutamine improves selectivity towards matriptase
at the expense of weakening its inhibitory activity.
Nevertheless, none of the modified inhibitors show
improvement in binding affinity to matriptase. This
major drawback can now be overcome by better aid
from the structural information of an experimentally
obtained structure of matriptase:SFTI-1 complex. This
work helps to define the structural basis of substrate
specificity of matriptase and provides more details in
the interactions between the inhibitor and protease. Our
structure also reveals the structural difference between
the SFTI-1 bound matriptase and trypsin complexes to
allow development of more potent and selective inhibi-
tors for matriptase.
Methods
Recombinant protein expression and Purification
The matriptase N164Q (chymotrypsin numbering) cata-
lytic domain mutant was first generated by site-directed
mutagenesis using cDNA encoding the entire protease
domain of human matriptase as template. The cDNA
was then amplified by PCR using primers containing
XhoI and SalI restriction sites. The purified PCR pro-
ducts were digested with XhoI and SalI and subcloned
into the XhoI-SalI sites of the Pichia pastoris (P. pas-
toris) expression vector pPICZaA (Invitrogen). Plasmid
DNAs were linearized with the restriction enzyme SacI
prior to transformation into P. pastoris strain X-33.
Recombinant matriptases were expressed in P. pastoris
according to the manufacturer’s recommendations. P.
pastoris expression medium was concentrated 10-20
fold using a Millipore concentrator (8000 Da MWCO
Figure 4 Solvent-accessible surfaces of (A) matriptase and (B) trypsin are colored by electrostatic potential (-7 to +7 kT/e in blue to
red) computed by APBS [48]. The matriptase active site surface is more acidic than that of trypsin.
Table 2 Calculated binding energies of cation-π
interactions between matriptase and SFTI-1 [34]
SFTI-1 side
chain
Matriptase aromatic
side chain
E(electrostatic)
(kcal/mol)
E(van der
Waals)
(kcal/mol)
Arg2 Phe97 -2.86 -1.17
Arg2 Phe99 -2.01 -1.19
Arg2 Trp215 -3.76 -1.01
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trated medium was applied onto a benzamidine column
(GE Healthcare) equilibrated with 50 mM Tris, 0.5 M
NaCl, pH7.4, and eluted with 100 mM glycine, pH 3.0.
The elution fractions were neutralized with 1 M Tris
pH 9 immediately. Fractions containing matriptase
activity were pooled and concentrated, and passed
through MonoQ column (Amersham Biosciences, Inc.)
pre-equilibrated with 40 mM Tris. The protein was
eluted in a buffer containing 40 mM Tris, pH7.4 with a
0-0.4 M NaCl gradient. Fractions containing protein
were pooled and concentrated to 5 mg/ml. Aliquots of
the purified protein were frozen at 193 K for crystalliza-
tion experiments.
Crystallization of b-matriptase-N164Q complex with its
inhibitors
For protein crystallization, b-matriptase-N164Q:benza-
midine complexes were mixed at 1:10 ratio, and crys-
tallized by the hanging-drop vapor diffusion method
with a precipitant solution of 0.1 M Tris, pH 8.0, 1.5
M ammonium sulfate, 3% ethanol. SFTI-1 was synthe-
sized by solid state synthesis as previously reported
[39]. The complex of b-matriptase-N164Q with SFTI-1
was crystallized with a precipitant condition of 22%
polyethylene glycol 8000, 0.1 M Tris pH 8 and 20 mM
CaCl2.
Data collection, structure solution and refinement
X-ray diffraction data were collected at APS to 1.2 Å
and 2.0 Å for b-matriptase-N164Q:benzamidine and b-
matriptase-N164Q:SFTI-1 complexes, respectively
(Table 3). The crystal structures of the complexes were
solved using the program MOLREP [40] from the CCP4
program suite [41] and the published b-matriptase
structure (Protein Data Bank (PDB) ID: 1EAX) [30] as
the search model. After refinement using the REFMAC
program [42], the Fo-Fc difference electron density
showed extra electron density attaching to Cys122.
Based on the contour of this extra electron density, a
molecule of reduced glutathione (GSH) was modeled
covalently linking to Cys122 (Additional file 1). In the
structure of b-matriptase-SFTI-1 complex, SFTI-1 was
modeled into the extra electron density around matrip-
tase active pocket. The resulting models were refined
using Phenix [43], and manual model fitting was carried
out using the program COOT [44]. In the final cycles of
refinement, TLS & restrained refinement with twenty
TLS groups which generated by the TLS motion deter-
mination (TLSMD) server [45] was applied. Detailed
refinement and structure statistics are listed in Table 3.
The final structures were analyzed by PROCHECK [46]
and PYMOL [47].
Additional material
Additional file 1: Fig. S1. The extra electron density (in stereo
representation) around the Cys122 of the b-matriptase-N164Q:
benzamidine structure suggests the Cys122 is conjugated by a disulfide
bond (yellow) to a glutathione (GSH, in green sticks). GSH might have
attached to the protein during protein synthesis because GSH is one of
the abundant intracellular sulfhydryl antioxidants in yeast as a similar
observation was made in other structures including the rhFXI-
benzamidine complex 49 where the protein was also expressed in P.
pastoris . 2Fo-Fc electron density map is contoured at 1s at 1.2 Å.
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Table 3 Statistics of X-ray diffraction data collection and
structure refinement
b-matriptase-N164Q:
benzamidine
b-matriptase-
N164Q:SFTI-1
Diffraction data
Space group C222 P41212
Cell parameters (Å) 66.9, 141.7, 52.0 75.9, 75.9, 94.1
Rmerge (%)
a 0.1 (0.5)
a 0.1 (0.5)
a
Completeness (%) 91.6 (94.6)
a 98.9 (100.0)
a
Average I/s 18.3 (1.5)
a 38.5 (3.0)
a
Data redundancy 5.7 (2.9)
a 12.1 (11.1)
a
Refinement
Resolution (Å) 70.9-1.2 25.8-2.0
Rwork/Rfree (%) 17.8/19.9 19.4/24.5
RMSD
Bond length
(Å)
0.006 0.003
Bond angles
(°)
1.20 0.70
Mean B factors (Å
2) 12.5 50.7
Ramachandran plot, % residues in regions:
Most favored 97.5 96.4
Additionally
allowed
2.5 3.6
Generously
allowed
00
Disallowed 0 0
PDB ID Code 3P8G 3P8F
aNumbers in the parentheses are for the highest resolution shell.
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